The Association Between the Hemoglobin Glycation Index and Cardiometabolic Diseases: A Mini‐Review

作者：Qingwen Wu, Li-Rong Mo, J. Nan, Wan-Zhong Huang, Qiang Wu, Qiang Su · 发表于：The Journal of Clinical Hypertension · 年份：2025 · DOI：10.1111/jch.70092 · 被引用次数：6 · 研究领域：Medicine

The hemoglobin glycation index (HGI) has emerged as a pivotal biomarker for evaluating long‐term glycemic control, offering a more comprehensive assessment compared with conventional glycated hemoglobin (HbA1c) measurements. Elevated HGI levels are significantly correlated with the incidence of cardiometabolic diseases (CMDs). This review synthesizes current evidence on the clinical utility of the HGI across coronary artery disease (CAD), hypertension, heart failure (HF), diabetes mellitus (DM), serum uric acid (SUA) levels, and nonalcoholic fatty liver disease (NAFLD), thereby providing clinicians with an enhanced framework for precise disease stratification, therapeutic optimization, and prognostic prediction.